ライフサイエンスコーパス: ursodiol

1 ted serum bile acids responded positively to ursodiol.

2 e alone or in combination with colchicine or ursodiol.

3 s despite treatment with corticosteroids and ursodiol.

4 n a randomized, double-blind study comparing ursodiol (13 to 15 mg per kilogram of body weight per da

5 , patients were randomly assigned to receive ursodiol, 300 mg twice daily (or 300 mg in the morning a

6 ed in combination with ursodeoxycholic acid (ursodiol), a naturally occurring 7-B-epimer of the bile

7 Treatment with ursodiol, a more hydrophilic bile acid, improved pruritu

8 re likely to progress despite treatment with ursodiol and understand the putative new bile acid and i

9 linical trials demonstrating the efficacy of ursodiol as a treatment for PBC were published, although

10 of obeticholic acid or placebo, 93% received ursodiol as background therapy.

11 Ursodiol, but not placebo, was associated with improveme

12 Unconjugated ursodiol bypassed the hepatic uptake block to enlarge th

13 In contrast, unconjugated ursodiol entered the liver and was conjugated and secret

14 as not statistically significant (13% in the ursodiol group and 20% in the placebo group; P > 0.2).

15 e (relative risk of treatment failure in the ursodiol group, 1.01; 95 percent confidence interval, 0.

16 acebo group and 16 of 31 (52 percent) in the ursodiol group.

17 Ursodiol has been shown to protect against development o

18 Ursodiol improves serum aminotransferase levels in chron

19 investigating the chemoprotective effect of ursodiol in patients with ulcerative colitis may be warr

20 er liver transplantation, and the success of ursodiol in treatment.

21 Here, we confirmed that ursodiol inhibits C. difficile R20291 spore germination

22 ondary bile acid ursodeoxycholic acid (UDCA; ursodiol) inhibits the life cycles of various strains of

23 e in vivo However, the mechanism(s) by which ursodiol is able to restore colonization resistance agai

24 e published, although it has been clear that ursodiol is not a cure and only delays progression in so

25 e FDA-approved formulation of UDCA, known as ursodiol, may be able to restore colonization resistance

26 Obeticholic acid administered with ursodiol or as monotherapy for 12 months in patients wit

27 Treatment of primary biliary cirrhosis with ursodiol or colchicine may stabilize the disease or slow

28 7 patients who had an inadequate response to ursodiol or who found the side effects of ursodiol unacc

29 Although ursodiol pretreatment did not result in a consistent dec

30 Ursodiol pretreatment resulted in attenuation of CDI pat

31 Ursodiol prophylaxis seemed to decrease the incidence of

32 well-defined primary sclerosing cholangitis, ursodiol provided no clinical benefit.

33 ebo recipients and 15% (5 of 34 patients) in ursodiol recipients (P = 0.03).

34 Ursodiol remains a viable nonantibiotic treatment and/or

35 ne model of CDI, exogenous administration of ursodiol resulted in significant alterations in the bile

36 On ursodiol therapy, hepatic bile acid synthesis was enhanc

37 can progress to cirrhosis and death despite ursodiol therapy.

38 to ursodiol or who found the side effects of ursodiol unacceptable to receive obeticholic acid at a d

39 Ursodiol (ursodeoxycholic acid) benefits patients with p

40 Ursodiol use appears to be associated with a lower frequ

41 The association between dysplasia and ursodiol use remained after adjustment for sex, age at o

42 Ursodiol use was strongly associated with decreased prev

43 Use of ursodiol was assessed in all patients.